Don’t Use Chloroquine As COVID-19 Treatment, NAFDAC Warns Nigerians

The National Agency for Food and Drug Administration and Control has cautioned Nigerians against the utilization of Chloroquine to treat Coronavirus. 

Mojisola Adeyeye, NAFDAC's Director-General, told writers in Abuja that all COVID-19 patients must submit themselves to a specialist. 

She stated, "No one should purchase Chloroquine and use it. On the off chance that you have COVID-19, go to a specialist. We have cautioned Nigerians and will do that once more. Try not to take Chloroquine. 

"The postponement in affirming a portion of the medications for treatment of the infection is a result of the clinical preliminaries the organization is completing on them. 

"Up until now, no gathering or individual has proffered any answer for the treatment or the executives of the pandemic." 

Adeyeye said the Chinese Government completed heaps of preliminaries on Chloroquine before it affirmed its utilization for treatment on some COVID-19 patients. 

She included, "Clinical preliminary isn't a thing one can deal with coolly; it requires direction, oversight and trial before endorsement so it won't bring on additional harm. 

"The preliminary is to decide if it is really working or not, after a supported perception. NAFDAC should be the focal point of the guideline of clinical preliminary impacts. 

"It's not possible for anyone to carry out any responsibility of clinical preliminary in the facility or anyplace without going through NAFDAC convention. 

"In the event that such a convention is discovered faulty or will in general trade off the wellbeing of Nigerians, we won't affirm it.'' 

The NAFDAC manager further said whatever methodology was coming up for the fix or reduction of COVID-19 must be submitted for preliminary to the organization for suitable handling. 

She said the office should likewise guarantee that all the systems utilized in showing up at their exploratory procedures for the fix or decrease of COVID-19 must be submitted with significant evidence. 

Mrs Adeyeye prompted analysts and conventional clinical experts to follow the typical convention before the endorsement of their work for open utilization.